Tuesday, June 1, 2010

Omnitrope becomes first recommended biosimilar

The National Institute for Health and Clinical Excellence has recommended Omnitrope as the first biosimilar to be recommended for treatment. This biosimilar can be used in the treatment of growth failure in children.

Ameet Mallik, global head of Sandoz Biopharmaceuticals, stated:
"This is an important decision, the ramifications of which go far beyond the UK. Biosimilars, pioneered by Sandoz, are recognized around the world as having comparable safety, efficacy and quality to existing biopharmaceuticals following loss of patent protection.”

Read the full article here.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment